BioNTech | Sustainability Performance
BioNTech SE is engaged in biotechnology research and development, primarily focused on developing innovative therapies and vaccines for various diseases and conditions.
2008
Germany
5,001 - 10,000 employees
Biotechnology
$1B - 10B in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#5339
Overall#256
in Germany#85
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Environmental
Digital emissionsEnergy consumptionGovernance
Targets
Renewable energy
Aligned
Renewable electricity
Reveal data for 1 credit
85%2023
Industry rank: 9 out of 251
Total electricity consumption
and % renewables
(MWh, % of consumption)
Industry rank: 9 out of 251
Total electricity
Share of renewable electricity
Industry benchmark
Digital Emissions
CO2e per visit (g)
Industry benchmark
B/M 0.26 g
B
Environmental ScoreScore B
Green HostingNo
Controversy level
- BioNTech has faced multiple US patent infringement disputes over its Comirnaty mRNA COVID-19 vaccine including the 2024 USD 791 million Moderna patent ruling, plus the contested 2023 mass layoffs and sustained pharmaceutical pricing scrutiny over US/EU commercial-rate pricing transitions.
Sustainability targets and commitments
| Target | Year | Value | Scope | Baseline |
|---|
